BioAtla, Inc.

What they do

BioAtla develops CAB antibody therapeutics that selectively bind to tumor antigens under acidic pH conditions to reduce on-target, off-tumor toxicity. Its pipeline includes completed Phase 2 trials for mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), evalstotug (BA3071), and an ongoing Phase 1 trial for BA3182 (CAB-EpCAM x CAB-CD3). The company has no approved products and generates revenue primarily through collaboration and licensing agreements.

Revenue drivers

• Context Therapeutics license agreement — Collaboration revenue from the CAB-Nectin4-TCE program; recognized $2.0 million in 2025 (milestone payment) and $11.0 million in 2024 (upfront payment).
• Government and other collaboration revenue — Historical annual revenue of $300,000 in 2021; minimal or no product sales, with collaboration revenue being the primary source.
• Pre-funded and other financing arrangements — Non-operating income from warrant liabilities and Pre-paid Advance Agreements (PPAs) affect net income but are not core revenue drivers.

Recent performance

For full year 2025, BioAtla reported a net loss of $59.6 million, an improvement from $69.8 million in 2024. R&D expenses fell to $43.6 million in 2025 from $63.1 million in 2024; G&A expenses fell to $17.7 million from $21.8 million. In Q2 2026, the company reported net income of $0.5 million (three months) and a net loss of $5.9 million (six months), compared to net losses of $18.7 million and $34.0 million for the same periods in 2025. As of June 30, 2026, cash and equivalents were $1.5 million, total assets $9.5 million, and shareholder equity was negative $36.2 million.

Strategy

Management initiated a formal process in March 2026 to explore strategic options, including asset sales, licensing, partnerships, or other corporate transactions, with Tungsten Advisors as exclusive financial advisor. To preserve capital, the company implemented a reduction in force and paused further enrollment in the Phase 1 BA3182 study, while continuing follow-up of existing patients. The company is re-evaluating the timing and pace of enrollment for BA3182 and the timeline to commence a Phase 3 study for ozuriftamab vedotin (BA3021) in 2L+ OPSCC. Prior restructuring in March 2025 included a 30% workforce reduction. There can be no assurance the strategic process will result in any transaction.

Risks

• Going concern / liquidity — Cash and equivalents of $1.5 million as of June 30, 2026, with negative shareholder equity, raise substantial doubt about the ability to continue as a going concern.
• Strategic process uncertainty — The formal process to monetize assets may not result in any agreements or transactions, and no assurances exist that clinical development will not be limited or delayed.
• Clinical and regulatory risk — All product candidates are in clinical development; failure to obtain regulatory approval would preclude commercialization and revenue generation.
• Dependence on collaboration revenue — Revenue relies on milestone payments from partners like Context Therapeutics; such payments are lumpy and not guaranteed.

Outlook

Management expects R&D and G&A expenses to continue declining in 2026 following the March 2026 workforce reduction and cost-containment measures. The company is focused on supporting the ongoing Phase 1 study of BA3182 while preserving capital, but development may be limited or delayed pending the strategic review. No guidance on revenue or profitability was provided, and the company expects to incur significant operating expenses for the foreseeable future.